ROYCE & ASSOCIATES LP - TETRAPHASE PHARMACEUTICALS I ownership

TETRAPHASE PHARMACEUTICALS I's ticker is TTPHXXXX and the CUSIP is 88165N105. A total of 79 filers reported holding TETRAPHASE PHARMACEUTICALS I in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
ROYCE & ASSOCIATES LP ownership history of TETRAPHASE PHARMACEUTICALS I
ValueSharesWeighting
Q2 2019$254,000
-64.1%
527,9000.0%0.00%
-66.7%
Q1 2019$707,000
+31.2%
527,900
+10.7%
0.01%
+20.0%
Q4 2018$539,000
-59.0%
476,9000.0%0.01%
-44.4%
Q3 2018$1,316,000
+136.7%
476,900
+206.1%
0.01%
+125.0%
Q2 2018$556,000155,8000.00%
Other shareholders
TETRAPHASE PHARMACEUTICALS I shareholders Q1 2019
NameSharesValueWeighting ↓
HARVEY CAPITAL MANAGEMENT INC 354,300$7,068,0002.77%
Opaleye Management Inc. 169,700$3,385,515,0002.64%
Broadfin Capital, LLC 959,247$19,137,0002.01%
Novo Holdings A/S 900,000$17,955,0001.75%
Eventide Asset Management 300,900$6,003,0000.84%
EAM Investors, LLC 152,595$3,044,0000.62%
COLUMBIA PARTNERS L.L.C. INVESTMENT MANAGEMENT 497,858$9,932,0000.51%
Granite Point Capital Management, L.P. 40,000$798,0000.40%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 450,191$8,981,0000.33%
TFS CAPITAL LLC 133,070$2,655,0000.23%
View complete list of TETRAPHASE PHARMACEUTICALS I shareholders